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Aims Patients with diabetes mellitus (DM) have increased platelet reactivity and reduced platelet response to clopidogrel
compared with patients without DM. Prasugrel, a more potent antiplatelet agent, is associated with greater
reductions in ischaemic events compared with clopidogrel, particularly in patients with DM. The aim of this study
was to perform serial pharmacodynamic assessments of prasugrel with high-dose clopidogrel in patients with DM.
Methods
and results
Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 was a prospective, randomized, double-blind,
crossover study in patients with type 2 DM and coronary artery disease (CAD). Patients (n ¼ 35) were randomly
assigned to either prasugrel 60 mg loading dose (LD)/10 mg maintenance dose (MD) or clopidogrel 600 mg LD/
150 mg MD over two 1-week treatment periods separated by a 2-week washout period. Platelet function was
assessed by VerifyNow
w P2Y12 assay, light transmission aggregometry, and vasodilator-stimulated phosphoprotein
phosphorylation at 0, 1, 4, and 24 h and 7 days. Greater platelet inhibition by VerifyNow
w P2Y12 was achieved by
prasugrel compared with clopidogrel at 4 h post-LD (least squares mean, 89.3 vs. 27.7%, P , 0.0001; primary end-
point). The difference in platelet inhibition between prasugrel and clopidogrel was signiﬁcant from 1 h through 7
days (P , 0.0001). Similar results were obtained using all other platelet function measures. Prasugrel resulted in
fewer poor responders at all time points irrespective of deﬁnition used.
Conclusion In patients with type 2 DM and CAD, standard-dose prasugrel is associated with greater platelet inhibition and better
response proﬁles during both the loading and maintenance periods when compared with double-dose clopidogrel.
Clinical trial identiﬁer: www.clinicaltrials.gov—NCT00642174
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Patients with diabetes mellitus (DM) are characterized by
enhanced platelet reactivity and a reduced response to oral antipla-
telet medications used for the prevention of ischaemic events.
1–3
Platelets from patients with DM demonstrate upregulation of
several signalling pathways, which may explain the increased preva-
lence of low platelet inhibition following clopidogrel treatment and
contribute to increased atherothrombotic risk in these patients
compared with those without DM.
1,4 Therefore, greater platelet
P2Y12 receptor inhibition may provide more optimal platelet inhi-
bition in this high-risk patient population. In the Optimizing anti-
Platelet Therapy In diabetes MellitUS (OPTIMUS)-1 Study, a high
proportion of patients had a suboptimal response to a standard
dose of clopidogrel. Although a high maintenance dose (MD) of
clopidogrel (150 mg per day) enhanced platelet inhibition in
patients with DM presenting with elevated platelet reactivity
while on standard treatment regimens, a considerable proportion
of the population maintained persistently elevated platelet function
despite the more aggressive P2Y12 receptor blockade.
5 These
results demonstrate the need for alternative platelet inhibition
strategies for this high-risk patient population.
Prasugrel is a thienopyridine that produced a greater reduction
in ischaemic events than clopidogrel but with increased risk of
bleeding in moderate-to-high-risk patients with acute coronary
syndrome undergoing percutaneous coronary interventions
(PCIs) in the Trial to Assess Improvement in Therapeutic Out-
comes by Optimizing Platelet Inhibition with Prasugrel-
Thrombolysis in Myocardial Infarction (TRITON-TIMI 38).
6 In the
subgroup of patients with DM in TRITON, a 30% relative risk
reduction with prasugrel vs. clopidogrel in the primary composite
endpoint of cardiovascular death, non-fatal myocardial infarction,
or non-fatal stroke was demonstrated without an increased risk
of major bleeding.
7 However, randomization was not stratiﬁed
by diabetic status in this clinical study and there was no signiﬁcant
interaction between patients with and without diabetes. Addition-
ally, two studies have examined, in non-randomized subgroup ana-
lyses, the pharmacodynamic proﬁles of prasugrel and clopidogrel in
stable coronary artery disease (CAD) patients with DM.
8,9
However, neither of these analyses was from a prospectively
deﬁned trial in a well-characterized DM population.
In patients with DM, a prospective comparison of the pharmaco-
dynamicproﬁlesofprasugrelwithhigherthanapprovedloadingdose
(LD) and MD of clopidogrel is largely unexplored in a prospectively
deﬁnedtrial.Therefore,theaimofthepresentstudywastocompare
the pharmacodynamic activity of standard-dose prasugrel with
double-dose clopidogrel in patients with type 2 DM who have
CADbymeansofmultipleplateletfunctionassays.Wehypothesized
that prasugrel would achieve greater platelet inhibition compared
with double-dose clopidogrel in these patients.
Methods
Patient population and study design
OPTIMUS-3 was a prospective, randomized, double-blind, double-
dummy, active-controlled, two-period crossover study conducted
between April 2008 and January 2009 at four academic sites in the
USA. Patients with type 2 DM between 18 and 75 years of age
treated with oral and/or parenteral hypoglycaemic therapy for at
least 1 month were enrolled. All patients had known CAD and were
taking aspirin (81–325 mg/day). Patients were ineligible to participate
if any of the following criteria was met: a deﬁned need for thienopyr-
idine therapy (e.g. within 12 months of an acute coronary syndrome
event or placement of a drug eluting stent; or within 1 month of place-
ment of a bare metal stent); within 30 days of coronary artery bypass
graft surgery or PCI without a stent placed; planned coronary revascu-
larization; glycosylated haemoglobin (HbA1c) ≥10 mg/dL within 3
months; treatment with ﬁbrin-speciﬁc ﬁbrinolytic therapy ,24 h or
non-ﬁbrin-speciﬁc ﬁbrinolytic therapy ,48 h prior to randomization;
presence of active internal bleeding or history of bleeding diathesis
or clinical ﬁndings associated with an increased risk of bleeding;
history of ischaemic or haemorrhagic stroke, transient ischaemic
attack, intracranial neoplasm, arteriovenous malformation, or aneur-
ysm; body weight ,60 kg; an international normalized ratio .1.5,
platelet count ,100 000/ mm
3, or haemoglobin ,10 gm/dL within 1
week of study entry.
The trial was conducted in agreement with the Declaration of Hel-
sinki and the International Conference on Harmonisation Guidelines
for Good Clinical Practice. The protocol was approved by the local
Ethics Review Committee or institutional review board at each parti-
cipating site, and all patients gave written informed consent before
undergoing any study procedure or receiving any study treatment.
A clinical research organization (CRO) was contracted by the
sponsor to hold the data and perform the data analysis after data
lock and then deliver the database and the analysis results to the
sponsor. An independent expert was contracted to check the quality
of the blinded data prior to the data analysis by the CRO.
Patients who met all criteria for enrolment were randomized at the
ﬁrst visit to double-blind treatment of either prasugrel 60 mg LD
orally followed by 10 mg/day MD for 7 days or clopidogrel 600 mg LD
orally [75 mg tablets Plavix
w (clopidogrel bisulfate; Bristol–Myers
Squibb/sanoﬁ-aventis, Bridgewater, NJ, USA)] followed by 150 mg/day
MD for 7 days (Figure 1A). The randomization ratio was 1:1 between
thetwotreatmentswithineachsite.Assignmenttotreatmentwasdeter-
mined by a computer-generated random sequence using an interactive
voiceresponsesystem.Prasugrelwasadministeredasthehydrochloride
salt in 10 mg tablets (Eli Lilly and Company, Indianapolis, IN, USA).
Patients were administered an equal number of identical tablets for
either the LDs (six prasugrel 10 mg tablets and eight placebo tablets
or eight clopidogrel 75 mg tablets and six placebo tablets) or MDs
(one prasugrel 10 mg tablet and two placebo tablets or two clopidogrel
75 mg tablets and one placebo tablet). Patients continued taking their
pre-study dosage of aspirin throughout the study. Platelet function
studies were performed at 0 (baseline), 1, 4, and 24 h, and 7 days (24 h
post last MD) after LD. After completion of the ﬁrst 1-week treatment
period, patients discontinued the study drug, and platelet function
studies were repeated 1 and 2 weeks later, with the 2-week measure
serving as the baseline (0 h) for the second treatment period. After
the 2-week washout period, patients received the other study drug
regimen for 1 week, during which assessment of platelet function mir-
rored the ﬁrst period. Final platelet function studies were performed 1
week after discontinuation of therapy.
Sample collection and platelet function
assays
Blood for platelet function analyses was collected from an antecubital
vein at pre-deﬁned time points into citrated tubes (Figure 1). Platelet
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w P2Y12 (Accumetrics, Inc., San
Diego, CA, USA), light transmission aggregometry (LTA), and
vasodilator-stimulated phosphoprotein phosphorylation (VASP-P)
expressed as the platelet reactivity index (PRI). The VerifyNow
w
P2Y12 assay is a rapid whole-blood point-of-care device and was uti-
lized according to the instructions of the manufacturer as described
previously.
10,11 Light transmission aggregometry was performed
according to standard protocols.
2,3,5 Maximum platelet aggregation
(MPA) was induced by 5 and 20 mM ADP and IPA% (IPA, inhibition
of platelet aggregation) was calculated as (baseline aggregation
response 2 post-dose aggregation response)/baseline aggregation
response × 100. Vasodilator-stimulated phosphoprotein phosphoryl-
ation was assessed as recommended by the manufacturer
5 using quan-
titative ﬂow cytometry and commercially available labelled monoclonal
antibodies (Biocytex, Inc., Marseille, France) at a central laboratory at
the University of Massachusetts.
Study endpoints
The primary endpoint of this study was IPA measured by the Verify-
Now
w P2Y12 assay 4 h after the administration of the study drug
LD. This time point was selected because the peak (≥95%) effect of
prasugrel 60 mg occurs by 2 h post-LD and is sustained past 4 h,
whereas the peak effect of a clopidogrel 600 mg LD has been
measured at ≤4 h in several studies.
12,13
Secondary measures included: IPA by VerifyNow
w P2Y12 at all other
time points; VerifyNow
w P2Y12 PRU, LTA (MPA and IPA), and VASP-P
PRI at all time points; and evaluation of the incidence of adverse events
such as thrombosis and haemorrhage. In addition, a responder-type
analysis was conducted in which a poor response to thienopyridine
treatment was deﬁned as: VerifyNow
w P2Y12 PRU .235
14;2 0mM
ADP LTA MPA .50%
5;2 0mM ADP LTA IPA ≤20%
15; or VASP-P
PRI .50%.
16 Finally, the possibility of ‘rebound’ platelet activation
was evaluated in an analysis of the pharmacodynamic effect of prasu-
grel 6–8 days after treatment discontinuation for each study period.
Rebound was considered to have occurred if, after the cessation of
the study drug, a ≥20% increase in platelet reactivity above the 0 h
value was obtained at the start of each treatment period. A cut-off
value of 20% was chosen because it is outside the range of assay
variability.
Statistical analysis
A sample size of 30 patients was required to provide at least 90%
power to detect a 17.5% difference in VerifyNow
w P2Y12 IPA
(primary endpoint) between treatment groups with a standard devi-
ation of 20% at a two-tailed signiﬁcance level of 0.05. This difference
was based on the response to MD therapy with prasugrel compared
with clopidogrel in a previous study available at the time of the
OPTIMUS-3 design.
17 All statistical comparisons of platelet function
between prasugrel and clopidogrel for the primary endpoint and sec-
ondary endpoints with continuous variables were conducted using a
linear mixed-effect model with treatment group, sequence, and
treatment-group-by-sequence (i.e. period) as ﬁxed effects and
patient as a random effect. Conﬁdence intervals (CI) and all tests of
statistical signiﬁcance for treatment comparisons were evaluated at a
two-tailed signiﬁcance level of 0.05 using SAS version 9.1. Results
are reported as the least-squares mean with 95% CI. Sensitivity analysis
on the primary endpoint was conducted after adjusting baseline IPA
values assessed by VerifyNow
w P2Y12 in the mixed-effect model. Cat-
egorical variables were analysed using Fisher’s exact tests.
All analyses of platelet function were conducted on the pharmaco-
dynamic population, which was deﬁned as all randomized subjects who
received at least one dose of study drug and had blood draws for IPA
Figure 1 (A) Study design. (B) Patient disposition.
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w P2Y12 4 h after the administration of the LD.
Safety analyses were conducted on the safety population, which
included all patients exposed to at least one dose of the study drug.
Safety was assessed by evaluating vital signs, all reports of bleeding,
and all reported adverse events including thrombotic cardiovascular
events, death, myocardial infarction, and stroke. Bleeding was classiﬁed
as major, minor, or insigniﬁcant according to the Thrombolysis In Myo-
cardial Infarction (TIMI) criteria.
6
Results
Forty-three patients were screened and 35 were randomly
assigned to either prasugrel (n ¼ 18) or clopidogrel (n ¼ 17) for
the ﬁrst treatment period (Figure 1B). Of these 35 patients, 34
completed both treatment periods and served as their own
control. One patient who was initially assigned to the clopidogrel
group in the ﬁrst treatment period was found to have an exclusion
criterion (HbA1c ≥10 mg/dL) and did not cross over to prasugrel.
Baseline characteristics are described in Table 1.
VerifyNow
w P2Y12 assay
At 4 h post-LD (primary endpoint), patients treated with prasugrel
had signiﬁcantly greater IPA compared with clopidogrel [89.3%
(95% CI ¼ 83.0–95.6) vs. 27.7% (95% CI ¼ 21.5–33.9), P ,
0.0001] (Figure 2A). Following  1 week of MD therapy, the IPA
was still signiﬁcantly greater with daily prasugrel 10 mg compared
with daily clopidogrel 150 mg [61.8% (95% CI ¼ 55.7–67.9) vs.
44.2% (38.1–50.3), P , 0.0001]. The difference between prasugrel-
and clopidogrel-treated patients was signiﬁcant at all time points
from1 hpost-LDthrough7days(24 hafterthelastMD).Thediffer-
ence between prasugrel- and clopidogrel-treated patients was also
signiﬁcant at all time points from 1 h post-LD through 7 days as
measured by VerifyNow
w P2Y12 PRU (Figure 2B). When measured
at 1 week following discontinuation of study drug, platelet function
for prasugrel- and clopidogrel-treated patients returned to near
baseline (Figure 2A and B). The results were consistent irrespective
of the use of insulin for glycaemic control (data not shown).
Light transmission aggregation
Figure 3A shows MPA to 20 mM ADP using LTA. Maximum platelet
aggregation values at 0 h for patients in both treatment groups
were similar. At 4 h post-LD, patients treated with prasugrel had
signiﬁcantly lower MPA compared with patients treated with
................................................................................
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Table 1 Baseline characteristics
Characteristic N 5 35
Age (years), mean+SD 61.3+8.8
Male, n (%) 24 (68.6)
Race, n (%)
Non-Hispanic white 15 (42.9)
Non-Hispanic black 7 (20.0)
Hispanic 8 (22.9)
Other 5 (14.3)
Body mass index (kg/m
2), mean+SD 33.1+8.2
Cardiovascular history, n (%)
Congestive heart failure 5 (14.3)
Hypertension 33 (94.3)
Hypercholesterolaemia 33 (94.3)
Prior myocardial infarction 13 (37.1)
Prior PCI 20 (57.1)
Prior coronary artery bypass graft 8 (22.9)
Current smoker 7 (20.0)
Obesity (body mass index ≥30) 17 (48.6)
Duration of CAD (years), mean+SD 3.1+3.3
Duration of type 2 DM (years), mean+SD 8.5+6.6
Antihyperglycaemic medication, n (%)
Insulin 7 (20.0)
Non-insulin 28 (80.0)
Aspirin dose, n (%)
81 mg/day 22 (62.9)
162 mg/day 1 (2.9)
325 mg/day 12 (34.3)
CAD, coronary artery disease; DM, diabetes mellitus; MI, myocardial infarction; N,
number of patients; n, number in group; PCI, percutaneous intervention; SD,
standard deviation.
Figure 2 Platelet function by VerifyNow
w P2Y12. (A) Inhibition
of platelet aggregation. (B) VerifyNow
w P2Y12 PRU. Values are
expressed as the least-squares mean and 95% conﬁdence inter-
vals. Prasugrel and clopidogrel values from each treatment
period have been combined. Time 0 is the baseline value (com-
bined for each treatment period). ***P , 0.0001.
Prasugrel vs. clopidogrel in diabetes 841clopidogrel [22.4% (95% CI ¼ 17.0–27.8) vs. 57.5% (52.2–62.8), P
, 0.0001]. Following  1 week of MD therapy, MPA was still
signiﬁcantly lower with prasugrel compared with clopidogrel
[38.3% (95% CI ¼ 33.0–43.6) vs. 50.7% (95% CI ¼ 45.4–56.0),
P , 0.0001]. The differences between prasugrel- and clopidogrel-
treated patients were signiﬁcant at all time points from 1 h
post-LD through 7 days. Similar ﬁndings were observed using
5 mM ADP (Figure 3B).
Figure 3C compares IPA by LTA in response to 20 mM ADP. At
4 h post-LD, IPA was signiﬁcantly greater for prasugrel compared
with clopidogrel [71.2% (95% CI ¼ 64.7–77.7) vs. 25.9% (19.6–
32.3), P , 0.0001]. Following  1 week of MD therapy, IPA was
still signiﬁcantly greater with prasugrel 10 mg daily compared
with clopidogrel 150 mg daily [50.5% (95% CI ¼ 44.0–56.9) vs.
34.5% (28.1–40.9), P , 0.0001]. The differences between
prasugrel- and clopidogrel-treated patients were signiﬁcant at all
time points from 1 h post-LD through 7 days. Similar ﬁndings
were observed using 5 mM ADP (Figure 3D).
Vasodilator-stimulated phosphoprotein
Baseline VASP PRI values for prasugrel- and clopidogrel-treated
patients were similar [83.5% (95% CI ¼ 78.8–88.3) vs. 80.6%
(95% CI ¼ 75.9–85.3), P ¼ 0.37] (Figure 4). At 4 h post-LD,
patients treated with prasugrel had signiﬁcantly lower platelet reac-
tivity by VASP PRI than patients treated with clopidogrel [14.5%
(95% CI ¼ 7.7–21.4) vs. 67.5% (95% CI ¼ 60.8–74.2), P ,
0.0001]. Following  1 week of MD therapy, VASP PRI was still sig-
niﬁcantly lower with prasugrel 10 mg daily compared with clopido-
grel 150 mg daily [27.4% (95% CI ¼ 20.8–34.0) vs. 42.3 (95% CI ¼
35.7–48.9), P ¼ 0.0012]. The difference between prasugrel- and
clopidogrel-treated patients was signiﬁcant at all time points
from 1 h post-LD through 7 days.
Response proﬁles
Figure 5 shows individual patient VerifyNow
w P2Y12 PRU values at
baseline (0 h) and 4 h post-LD during the clopidogrel-to-prasugrel
crossover sequence (Figure 5A) and the prasugrel-to-clopidogrel
crossover sequence (Figure 5B). After the prasugrel 60 mg LD,
PRU was generally lower than that achieved after the clopidogrel
600 mg LD, regardless of whether prasugrel was administered in
the ﬁrst or second treatment period. Figure 5 also illustrates less
variability in response to prasugrel compared with clopidogrel.
Three patients treated with clopidogrel achieved response rates
comparable with those treated with prasugrel.
Figure 6 presents the results of the poor responder analysis at 4
and 24 h post-LD and at 7 days. Regardless of the deﬁnition used,
Figure 3 Platelet aggregation by light transmission aggregometry. (A) Maximum platelet aggregation to 20 mM ADP; (B) maximum platelet
aggregation to 5 mM ADP; (C) inhibition of platelet aggregation in response to 20 mM ADP; (D) inhibition of platelet aggregation in response
to 5 mM ADP. Values are expressed as the least-squares mean and 95% conﬁdence intervals. Prasugrel and clopidogrel values from each treat-
ment period have been combined. Time 0 is the baseline value (combined for each treatment period). *P ¼ 0.0002, **P ¼ 0.0001,
***P , 0.0001.
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compared with prasugrel (all P-values ,0.05). At 4 h post-LD, the
rate of poor responders ranged from 0 to 3.1% for prasugrel and
from 35.3 to 82.9% for clopidogrel. At 24 h post-LD, the rate of
prasugrel poor responders was 0% regardless of deﬁnition com-
pared with 51.5–78.8% for clopidogrel. At 7 days, the poor
responder rate ranged from 2.9 to 21.2% for prasugrel and from
23.5 to 52.9% for clopidogrel.
Rebound platelet activation
One patient on prasugrel and one patient on clopidogrel met
rebound criteria by MPA but not by the other assays. Similarly,
one prasugrel patient met rebound criteria by VerifyNow
w
P2Y12 PRU; one patient on prasugrel and two patients on clopido-
grel met rebound criteria according to PRI using VASP-P; and none
of these patients met rebound criteria using the other assays. No
patient meeting rebound criteria on clopidogrel or prasugrel met
criteria with the alternative drug.
Safety
Major or minor bleeding by TIMI criteria did not occur with either
treatment regimen. Two TIMI minimal bleeding events that
occurred within 24 h of the last MD were observed in clopidogrel-
treated patients. One prasugrel-treated patient experienced a
vessel puncture site bleed. None of these episodes required inter-
vention to control bleeding. No deaths or other serious adverse
events occurred during the study. The incidence of adverse
events in the prasugrel group was 14.7% (5/34), and 25.7%
(9/35) in the clopidogrel group. The types of adverse events in
the prasugrel and clopidogrel groups were similar (Table 2). No
patients discontinued due to an adverse event.
Discussion
The results of the OPTIMUS-3 study conﬁrm the hypothesis that
treatment with prasugrel 60 mg LD/10 mg MD is associated with
greater platelet inhibition than double-dose clopidogrel 600 mg
LD/150 mg MD in a prospectively deﬁned study in patients with
type 2 DM and CAD. This study enrolled a well-characterized
population of patients with DM, unlike previous studies. Platelet
Figure 4 Platelet function by vasodilator-stimulated phospho-
protein. Vasodilator-stimulated phosphoprotein platelet reactivity
index values are expressed as the least-squares mean and 95%
conﬁdence intervals. Prasugrel and clopidogrel values from each
treatment period have been combined. Time 0 is the baseline
value (combined for each treatment period). **P , 0.01,
***P , 0.0001.
Figure 5 Individual response proﬁles. VerifyNow
w P2Y12 PRU was measured at 0 h (baseline) and 4 h post-loading dose of prasugrel or clo-
pidogrel. (A) Patients dosed with clopidogrel ﬁrst and then crossed over to prasugrel. (B) Patients dosed with prasugrel ﬁrst and then crossed
over to clopidogrel. Baseline (0 h) values for the second treatment period were measured after the 2-week washout period. BL, baseline.
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ments using different methodologies, including point-of-care
testing, LTA, and ﬂow cytometry, which encompassed a range of
speciﬁcities for P2Y12-mediated platelet activation. This higher
level of platelet inhibition in prasugrel-treated patients was
evident at the ﬁrst measurement (1 h post-LD) and continued
over 24 h. Although the level of platelet inhibition after 1 week
of prasugrel 10 mg MD was lower than the prasugrel LD, as the
need for very high levels of platelet inhibition is probably not
required in the absence of a procedure, the level of inhibition
associated with the prasugrel 10 mg MD was signiﬁcantly higher
than with clopidogrel 150 mg MD. This study also provides
additional information on clopidogrel’s poor response in patients
with DM, examines potential rebound after 7 days of drug withdra-
wal, and provides adverse event data in the study population.
Numerous studies have demonstrated the clinical beneﬁt associ-
ated with platelet P2Y12 receptor inhibition with clopidogrel, par-
ticularly in high-risk patients.
18,19 However, patients with DM
continue to have a higher risk of recurrent ischaemic events, includ-
ing stent thrombosis, compared with patients without DM despite
the use of clopidogrel.
1,18 This may be attributed, at least in part,
to the greater prevalence of suboptimal P2Y12 inhibition achieved
withrecommendedregimensofclopidogrelthathasbeenassociated
with a higher risk of atherothrombotic complications.
1 These
Figure 6 Poor responders. Poor responder analyses were con-
ducted at (A) 4 h post-loading dose; (B) 24 h post-loading dose;
and (C) 7 days by VerifyNow
w (PRU .235), light transmission
aggregometry (MPA .50% and IPA ≤20%), or vasodilator-
stimulated phosphoprotein phosphorylation (PRI .50%) platelet
function assays. P-values for comparison between treatment
groups for each assay are indicated. MPA, maximum platelet
aggregation to 20 mM ADP by light transmission aggregometry;
IPA, inhibition of platelet aggregation with 20 mM ADP by light
transmission aggregometry.
................................................................................
Table 2 Summary of adverse events in the safety
population of the OPTIMUS-3 Study
Adverse event Prasugrel 60 mg
LD/10 mg MD
(n 5 34), n (%)
Clopidogrel 600 mg
LD/150 mg MD
(n 5 35), n (%)
Number of patients
with at least one
event
5 (14.7) 9 (25.7)
Number of events 8 19
Haematocrit
decreased
a
1 (2.9) 0
Haemoglobin
decreased
a
1 (2.9) 0
Headache 1 (2.9) 2 (5.7)
Pain in extremity 1 (2.9) 0
Upper respiratory
tract infection
1 (2.9) 1 (2.9)
Urinary tract
infection
1 (2.9) 0
Vessel puncture site
haemorrhage
1 (2.9) 0
Contusion 0 1 (2.9)
Diarrhoea 0 1 (2.9)
Electrolyte
imbalance
0 1 (2.9)
Epistaxis 0 1 (2.9)
Haemorrhage 0 1 (2.9)
Nausea 0 1 (2.9)
Respiratory tract
congestion
0 1 (2.9)
Rhinorrhoea 0 1 (2.9)
Sinusitis 0 1 (2.9)
Vomiting 0 1 (2.9)
Wart excision 0 1 (2.9)
aInvestigator deﬁned.
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particularly in high-risk patients such as those with DM.
The OPTIMUS-1 study demonstrated that a high-clopidogrel
MD was associated with greater platelet inhibitory effects com-
pared with standard dosing in patients with DM and CAD who
presented with elevated platelet reactivity while on standard dual
antiplatelet therapy. However, inadequate platelet inhibition per-
sisted in 60% of patients.
5 In the PRINCIPLE-TIMI 44 Trial, the
rate of response to prasugrel 60 mg LD/10 mg MD was signiﬁcantly
greater than double-dose clopidogrel in the overall patient popu-
lation,
7 as well as in patients with DM.
9 The rate of poor respon-
ders in patients with DM at 24 h post-LD was  40%.
9 The
OPTIMUS-2 study showed that adjunctive treatment with cilosta-
zol (‘triple therapy’) enhances measures of platelet P2Y12 inhibition
in patients with DM and CAD to a greater extent than standard
dual antiplatelet therapy with aspirin and clopidogrel.
20 However,
cilostazol is poorly tolerated and has an elevated prevalence of
side effects that limit treatment compliance.
20 Results from a sub-
group of 19 patients with DM were presented by Erlinge et al.
8 in a
study examining the pharmacodynamic poor responder rate with
high dose clopidogrel compared with prasugrel. There was a
higher rate of poor responders as measured by LTA and VASP
in the patients receiving clopidogrel 600 mg LD/75 mg MD com-
pared with prasugrel 60 mg LD/10 mg MD for 28 days. These pre-
vious investigations suggested the need to explore better tolerated
treatment strategies, which provide more effective P2Y12 blockade,
as was assessed in the present study. The results from the
OPTIMUS-3 randomized trial in patients with DM conﬁrmed
earlier pharmacodynamic observations from subgroup analyses
that the rate of response to prasugrel was greater than the
response to clopidogrel despite the use of double the approved
clopidogrel dose.
19,21 Additionally, both prasugrel and clopidogrel
were well tolerated in this population with DM.
Clinical outcome data demonstrating an increase in recurrent
ischaemic events following withdrawal of thienopyridine therapy
suggest the potential for rebound in platelet reactivity.
22 Although
limited by the short duration of the current study, no consistent
evidence of a rebound effect was measured at either 1 week fol-
lowing discontinuation of study drug or at 2 weeks when the
second baseline (post crossover) was compared with the ﬁrst. If
rebound did exist, one would expect to ﬁnd it in the early
period when new, fully functional platelets would be the majority
of platelets in circulation. This was an exploratory analysis and
not speciﬁcally designed to examine rebound; therefore, results
of our study should be interpreted with caution but are consistent
with those reported by Sibbing et al.,
23 who found no evidence of
rebound platelet activity on clopidogrel withdrawal in a prospec-
tively deﬁned study. This suggests that the previously reported
increase in ischaemic events observed following thienopyridine
withdrawal may be the result of treatment cessation rather than
rebound platelet reactivity.
Study limitations
The aim of this study was to compare the antiplatelet effects of
prasugrel with double-dose clopidogrel in patients with DM; there-
fore, comparisons with patients without DM cannot be made.
Although adequately powered for the pharmacodynamic
endpoints, this study was conducted in a relatively small number
of patients, thus precluding an evaluation of clinical endpoints.
Additionally, the short duration of the trial did not allow for mean-
ingful assessment of bleeding events associated with antiplatelet
therapy and also limited conclusions regarding platelet function
and rebound following drug withdrawal to the time frame of the
study. Finally, patients included in the study were not indicated
for prasugrel or clopidogrel in order to allow a washout phase
without putting patients at risk. It should be underscored that in
the USA and Europe, prasugrel is indicated for ACS patients under-
going PCI, a population of patients not included in this study.
Conclusions
Compared with double-dose clopidogrel (600 mg LD/150 mg
MD), standard-dose prasugrel (60 mg LD/10 mg MD) resulted in
greater platelet inhibition in aspirin-treated patients with type 2
DM and CAD as assessed by multiple pharmacodynamic measures
in this prospective, randomized, double-blind, crossover study. Pra-
sugrel also resulted in a better response proﬁle with lower rates of
poor responders after both the LD and MD periods, irrespective
of platelet function assay or deﬁnition used. These ﬁndings may
explain the clinical beneﬁt observed with prasugrel in patients
with DM.
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